Cancer immune exclusion: breaking the barricade for a successful immunotherapy

Autores
Bruni, Sofia; Mercogliano, María Florencia; Mauro, Florencia Luciana; Cordo Russo, Rosalia Ines; Schillaci, Roxana
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving positive clinical resolutions rests upon the access of immune cells to the tumor. In this review, we focus on how the tumor microenvironment architecture, including stromal cells, immunosuppressive cells and extracellular matrix, protects tumor cells from an immune attack leading to immunotherapy resistance, and on the available strategies to tackle immune evasion.
Fil: Bruni, Sofia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Mercogliano, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Mauro, Florencia Luciana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Cordo Russo, Rosalia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Materia
EXTRACELLULAR MATRIX
IMMUNE EXCLUSION
MYELOID CELLS
PHYSICAL BARRIER
TUMOR INFILTRATING LYMPHOCYTES (TILS)
TUMOR MICROENVIRONMENT
TUMOR-ASSOCIATED MACROPHAGE (TAMS)
TUMOR-ASSOCIATED VASCULATURE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/216096
Acceder
id CONICETDig_192ae9439b81c6ed5c610e004ae61979
oai_identifier_str oai:ri.conicet.gov.ar:11336/216096
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Cancer immune exclusion: breaking the barricade for a successful immunotherapyBruni, SofiaMercogliano, María FlorenciaMauro, Florencia LucianaCordo Russo, Rosalia InesSchillaci, RoxanaEXTRACELLULAR MATRIXIMMUNE EXCLUSIONMYELOID CELLSPHYSICAL BARRIERTUMOR INFILTRATING LYMPHOCYTES (TILS)TUMOR MICROENVIRONMENTTUMOR-ASSOCIATED MACROPHAGE (TAMS)TUMOR-ASSOCIATED VASCULATUREhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving positive clinical resolutions rests upon the access of immune cells to the tumor. In this review, we focus on how the tumor microenvironment architecture, including stromal cells, immunosuppressive cells and extracellular matrix, protects tumor cells from an immune attack leading to immunotherapy resistance, and on the available strategies to tackle immune evasion.Fil: Bruni, Sofia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Mercogliano, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Mauro, Florencia Luciana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Cordo Russo, Rosalia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFrontiers Media2023-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/216096Bruni, Sofia; Mercogliano, María Florencia; Mauro, Florencia Luciana; Cordo Russo, Rosalia Ines; Schillaci, Roxana; Cancer immune exclusion: breaking the barricade for a successful immunotherapy; Frontiers Media; Frontiers in Oncology; 13; 3-2023; 1-252234-943XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3389/fonc.2023.1135456info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1135456/fullinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T12:02:14Zoai:ri.conicet.gov.ar:11336/216096instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 12:02:14.338CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Cancer immune exclusion: breaking the barricade for a successful immunotherapy
title Cancer immune exclusion: breaking the barricade for a successful immunotherapy
spellingShingle Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, Sofia
EXTRACELLULAR MATRIX
IMMUNE EXCLUSION
MYELOID CELLS
PHYSICAL BARRIER
TUMOR INFILTRATING LYMPHOCYTES (TILS)
TUMOR MICROENVIRONMENT
TUMOR-ASSOCIATED MACROPHAGE (TAMS)
TUMOR-ASSOCIATED VASCULATURE
title_short Cancer immune exclusion: breaking the barricade for a successful immunotherapy
title_full Cancer immune exclusion: breaking the barricade for a successful immunotherapy
title_fullStr Cancer immune exclusion: breaking the barricade for a successful immunotherapy
title_full_unstemmed Cancer immune exclusion: breaking the barricade for a successful immunotherapy
title_sort Cancer immune exclusion: breaking the barricade for a successful immunotherapy
dc.creator.none.fl_str_mv Bruni, Sofia
Mercogliano, María Florencia
Mauro, Florencia Luciana
Cordo Russo, Rosalia Ines
Schillaci, Roxana
author Bruni, Sofia
author_facet Bruni, Sofia
Mercogliano, María Florencia
Mauro, Florencia Luciana
Cordo Russo, Rosalia Ines
Schillaci, Roxana
author_role author
author2 Mercogliano, María Florencia
Mauro, Florencia Luciana
Cordo Russo, Rosalia Ines
Schillaci, Roxana
author2_role author
author
author
author
dc.subject.none.fl_str_mv EXTRACELLULAR MATRIX
IMMUNE EXCLUSION
MYELOID CELLS
PHYSICAL BARRIER
TUMOR INFILTRATING LYMPHOCYTES (TILS)
TUMOR MICROENVIRONMENT
TUMOR-ASSOCIATED MACROPHAGE (TAMS)
TUMOR-ASSOCIATED VASCULATURE
topic EXTRACELLULAR MATRIX
IMMUNE EXCLUSION
MYELOID CELLS
PHYSICAL BARRIER
TUMOR INFILTRATING LYMPHOCYTES (TILS)
TUMOR MICROENVIRONMENT
TUMOR-ASSOCIATED MACROPHAGE (TAMS)
TUMOR-ASSOCIATED VASCULATURE
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving positive clinical resolutions rests upon the access of immune cells to the tumor. In this review, we focus on how the tumor microenvironment architecture, including stromal cells, immunosuppressive cells and extracellular matrix, protects tumor cells from an immune attack leading to immunotherapy resistance, and on the available strategies to tackle immune evasion.
Fil: Bruni, Sofia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Mercogliano, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Mauro, Florencia Luciana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Cordo Russo, Rosalia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
description Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving positive clinical resolutions rests upon the access of immune cells to the tumor. In this review, we focus on how the tumor microenvironment architecture, including stromal cells, immunosuppressive cells and extracellular matrix, protects tumor cells from an immune attack leading to immunotherapy resistance, and on the available strategies to tackle immune evasion.
publishDate 2023
dc.date.none.fl_str_mv 2023-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/216096
Bruni, Sofia; Mercogliano, María Florencia; Mauro, Florencia Luciana; Cordo Russo, Rosalia Ines; Schillaci, Roxana; Cancer immune exclusion: breaking the barricade for a successful immunotherapy; Frontiers Media; Frontiers in Oncology; 13; 3-2023; 1-25
2234-943X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/216096
identifier_str_mv Bruni, Sofia; Mercogliano, María Florencia; Mauro, Florencia Luciana; Cordo Russo, Rosalia Ines; Schillaci, Roxana; Cancer immune exclusion: breaking the barricade for a successful immunotherapy; Frontiers Media; Frontiers in Oncology; 13; 3-2023; 1-25
2234-943X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3389/fonc.2023.1135456
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1135456/full
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846782357091123200
score 12.982451

Publicaciones similares